IATPO Partners with Viholabs Biotech SL

We are thrilled to announce an exciting new partnership between the International Association for the Treatment and Prevention of Obesity (IATPO) and Viholabs Biotech SL, a leading biotechnology company based in Barcelona, Spain. This collaboration marks a significant step forward in our mission to combat obesity—a global health challenge—through cutting-edge research and innovative solutions.

Viholabs Biotech SL is at the forefront of developing advanced therapeutic solutions targeting the brain-gut axis, a critical biological pathway linking the digestive system and the brain. This axis plays a pivotal role in regulating metabolism, appetite, and overall health, making it a key focus for understanding and treating conditions like obesity. Their flagship product, Viho® Obeglutide Spray, has already shown promising early results as a revolutionary approach to obesity management, leveraging their propietary innovative technology SynchroAxis designed for effectiveness and ease of use.

Through this partnership, IATPO and Viholabs aim to deepen our understanding of how brain-gut axis dysfunction contributes to obesity and related conditions. Together, we will:

• Conduct Joint Research and Clinical Studies: Collaborate on groundbreaking studies to explore the brain-gut axis’s role in obesity, leveraging Viholabs’ expertise in biotechnology and IATPO’s global network of health professionals and researchers.
• Develop Innovative Treatments: Combine Viholabs’ SynchroAxis technology—a pioneering approach to personalized medicine—with IATPO’s multidisciplinary framework to create safe, effective, and accessible obesity interventions.
• Raise Awareness: Educate communities and healthcare providers about the latest advancements in obesity treatment, emphasizing the brain-gut connection and its implications for long-term health.

This partnership opens up incredible opportunities for IATPO to expand its impact. With Viholabs, we can explore additional applications of brain-gut axis research, potentially addressing comorbidities like diabetes, depression, and neurodegenerative disorders—conditions often linked to obesity. We envision hosting international symposia, launching educational campaigns, and even developing digital tools (like apps or platforms) to support patients and clinicians in managing obesity more effectively.

Stay tuned for updates on this collaboration as we work together to transform the future of obesity treatment. To learn more about Viholabs Biotech SL and their innovative work, visit their website below.